Skip to main content

Table 2 Subjects with Adverse Events*

From: Subcutaneously administered Menopur(R), a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex(R) in subjects undergoing in vitro fertilization

Adverse Event Menopur® (n = 61) Repronex® (n = 64) P Value
Any 41 (67.2) 48 (75.0) 0.620
Severe 5 (8.2) 5 (7.8) 0.402
Serious 1 (1.6) 4 (6.3) 0.456
  1. *Values represent numbers (percentage) of subjects with one or more adverse event.